Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings Inc.

The latest announcement is out from Corbus Pharmaceuticals ( ($CRBP) ). On December 11, 2025, Corbus Pharmaceuticals announced the completion of it...

Corbus Pharmaceuticals Advances Obesity Treatment with CRB-913

Wedbush analyst initiated coverage with a Buy rating on Corbus Pharmaceuticals today and set a price target of $38.00. In a report released yesterd...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRBP	$9.70	+0.21%	496.99K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRBP	$9.70	+0.2%	496.99K
3
4
5
6

CRBP

CRBP

Dividend Overview

Get Corbus Pharmaceuticals Holdings Inc. Data in Excel

Get Corbus Pharmaceuticals Holdings Inc. Data in Excel